

**** Fee-For-Service Pharmacy Provider Notice #225 – November 2017 PDL Changes ****

April 26, 2018

Please be advised that the Department for Medicaid Services (DMS) is making changes to the Kentucky Medicaid Fee-For-Service (FFS) Pharmacy Preferred Drug List (PDL) based on recommendations and guidance as adopted by the Commissioner of the Department for Medicaid Services of the Cabinet for Health and Family Services by order dated December 22, 2017.

The Kentucky Medicaid FFS Pharmacy and Therapeutics Advisory Committee (Committee) met on November 16, 2017. A quorum was not achieved; however, the recommendations of the Committee were submitted for review. DMS, through its Commissioner, reviewed the recommendations and in consultation rendered its final decisions.

On May 29, 2018, the following changes will be effective:

Existing Drug Classes

Drug Class	The following products will remain <i>preferred</i> products:	The following products will become <i>preferred</i> products:	The following products will become <i>non-preferred</i> products and require prior authorization (PA):	The following products will remain <i>non-preferred</i> products and require prior authorization (PA):
Anti-Emetics: Other Oral Anti-Emetics: 5-HT3 Antagonists Oral Anti-Emetics: Δ-9-THC Derivatives Oral Anti-Emetics: NK-1 Antagonists	meclizine metoclopramide (EXCEPT ODT) prochlorperazine promethazine (EXCEPT 50 mg suppositories) Transderm-Scop® trimethobenzamide ondansetron dronabinol ^{CC, QL} Emend® capsules ^{QL}		Syndros™ ^{CC, QL} Emend® powder packets ^{QL}	Compazine® Compro® Diclegis™ ^{CC, QL} metoclopramide ODT Phenadoz® Phenergan® promethazine 50 mg suppositories Reglan® scopolamine transdermal system Tigan® Aloxi® ^{QL} Anzemet® granisetron Sancuso® ^{CC, QL} Varubi™ Zofran® Zuplenz® Cesamet® ^{CC, QL} Marinol® ^{CC, QL} Akynzeo® ^{QL} aprepitant ^{QL}

Drug Class	The following products will remain <i>preferred</i> products:	The following products will become <i>preferred</i> products:	The following products will become <i>non-preferred</i> products and require prior authorization (PA):	The following products will remain <i>non-preferred</i> products and require prior authorization (PA):
<p>First-Generation Antipsychotics</p> <p>Second-Generation Antipsychotics</p> <p>Antipsychotics: Injectable</p> <p>Atypical Antipsychotic and SSRI Comb.</p>	<p>amitriptyline/perphenazine chlorpromazine fluphenazine haloperidol loxapine Orap® perphenazine thioridazine thiothixene trifluoperazine</p> <p>aripiprazole tablets^{CC, QL} clozapine^{CC, QL} Latuda®^{CC, QL} olanzapine^{CC, QL} quetiapine^{CC, QL} risperidone^{CC, QL} Saphris®^{CC, QL} ziprasidone^{CC, QL}</p> <p>Abilify Maintena™^{CC, QL} fluphenazine decanoate^{CC, QL} Geodon®^{CC, QL} haloperidol decanoate^{CC, QL} haloperidol lactate^{CC, QL} Invega® Sustenna®^{CC, QL} Invega Trinza™^{CC, QL} olanzapine^{CC, QL} Risperdal® Consta®^{CC, QL} Symbyax®^{CC, QL}</p>	<p>quetiapine ER^{CC, QL}</p>	<p>clozapine ODT^{CC, QL} Fanapt™^{CC, QL} Seroquel® XR^{CC, QL}</p>	<p>Adasuve® pimozide</p> <p>Abilify® oral formulations^{CC, QL} Aripiprazole ODT, solution^{CC, QL} Clozaril®^{QL} FazaClo®^{QL} Geodon®^{QL} Invega®^{QL} Nuplazid™^{QL} paliperidone^{QL} Rexulti®^{QL} Risperdal®^{QL} Seroquel®^{QL} Versacloz®^{QL} Vraylar™^{QL} Zyprexa®^{QL} Aristada™ Haldol® Decanoate^{QL} Haldol® lactate^{QL} Zyprexa®^{QL} Zyprexa® Relprevv^{QL}</p> <p>olanzapine/fluoxetine^{QL}</p>
<p>Alpha Blockers for BPH</p>	<p>alfuzosin ER doxazosin tamsulosin terazosin</p>			<p>Cardura® Cardura XL® Flomax® Rapaflo™ Uroxatral®</p>

Drug Class	The following products will remain <i>preferred</i> products:	The following products will become <i>preferred</i> products:	The following products will become <i>non-preferred</i> products and require prior authorization (PA):	The following products will remain <i>non-preferred</i> products and require prior authorization (PA):
5-Alpha Reductase (5AR) Inhibitors	finasteride ^{CC}	dutasteride		Avodart® dutasteride/tamsulosin Jalyn® Proscar®
Immunomodulators	Enbrel® ^{CC, QL} Humira® ^{CC, QL}		Tremfya™ ^{CC, QL}	Actemra® ^{CC, QL} Cimzia® ^{CC, QL} Cosentyx® ^{CC, QL} Entyvio™ ^{CC, QL} Kevzara® ^{CC, QL} Kineret® ^{CC, QL} Orencia® ^{CC, QL} Otezla® ^{CC, QL} Remicade® ^{CC} Siliq™ ^{CC, QL} Simponi™ ^{CC, QL} Simponi™ ARIA ^{CC, QL} Stelara™ ^{CC, QL} Taltz® ^{CC} Xeljanz™ ^{CC, QL}
H. pylori Treatment	Pylera® ^{QL}		lansoprazole/amoxicillin /clarithromycin ^{QL}	Omeclamox-Pak™ ^{QL} Prevpac® ^{QL}
Hepatitis C: Direct-Acting Antiviral Agents Hepatitis C: Interferons Hepatitis C: Ribavirins	PEGASYS® ProClick ^{CC, QL} PEGASYS® syringe ^{CC, QL} ribavirin ^{CC}	Mavyret™ ^{CC, QL} Vosevi™ ^{CC, QL}	Daklinza™ ^{CC, QL} Eplclusa® ^{CC, QL} Technivie™ ^{CC, QL} Viekira XR and Pak® ^{CC, QL}	Harvoni® ^{CC, QL} Olysio™ ^{CC, QL} Sovaldi™ ^{CC, QL} Zepatier™ ^{CC, QL} PEGASYS® vial ^{CC, QL} PEGIntron™ ^{CC, QL} Copegus™ ^{CC} Moderiba™ ^{CC} Rebetol® ^{CC} Ribasphere™ ^{CC} Ribasphere RibaPak™ ^{CC} ribavirin dose pack ^{CC}
Anticonvulsants: Second Generation	Banzel™ ^{CC} Gabitril® gabapentin capsules, solution lamotrigine IR tablets, ODT levetiracetam IR tablets, solution Lyrica® ^{CC} Sabril® ^{CC} topiramate IR zonisamide	gabapentin tablets		Briviact® ^{QL} Fycompa™ gabapentin tablets Gralise™ Keppra™ tablets, solution Keppra XR™ Lamictal® Lamictal ODT® Lamictal® XR lamotrigine ER levetiracetam ER Neurontin® Qudexy XR™ tiagabine

Drug Class	The following products will remain <i>preferred</i> products:	The following products will become <i>preferred</i> products:	The following products will become <i>non-preferred</i> products and require prior authorization (PA):	The following products will remain <i>non-preferred</i> products and require prior authorization (PA):
				Topamax® topiramate ER Trokendi XR™ vigabatrin Vimpat® Zonegran®
Antidepressants: SNRIs	Savella™ CC venlafaxine venlafaxine ER capsules	<i>duloxetine DR (generic Cymbalta®)</i>		Cymbalta® desvenlafaxine ER base desvenlafaxine fumarate ER duloxetine (generic Irenka™) Effexor® Effexor XR® Fetzima™ Irenka™ Khedezla® Pristiq® venlafaxine ER tablets
Oral Oncology Agents, Hematologic Cancer	Alkeran® cladribine Gleevec® QL hydroxyurea Imbruvica™ CC, QL Jakafi™ CC, QL mercaptopurine Purixan® Rydapt® CC, QL Sprycel® QL Zolinza® QL Zydelig® CC, QL		<i>Idhifa® CC, QL</i>	Bosulif® QL Farydak® QL Hydrea® Iclusig™ QL imatinib QL melphalan Ninlaro™ Tassigna® QL Venclexta® QL
Stimulants and Related Agents	Adderall XR® CC, QL dexamethylphenidate IR CC, QL dextroamphetamine IR CC, QL dextroamphetamine ER CC, QL Focalin XR™ CC, QL guanfacine ER CC, QL Metadate ER® CC, QL Methylin® chewable tablets CC, QL methylphenidate IR tablets, capsules CC, QL methylphenidate ER/SA/SR CC, QL methylphenidate ER OROS CC, QL	atomoxetine CC, QL Vyvanse Chew CC, QL	Cotempla XR-ODT™ QL Mydayis™ QL Strattera® QL	Adderall® QL Adzenys XR-ODT™ QL Aptensio XR® QL clonidine ER QL Concerta® QL Daytrana™ QL Desoxyn® QL Dexedrine® QL dexamethylphenidate ER QL dextroamphetamine solution QL Dyanavel™ XR susp QL Evekeo™ QL Focalin™ QL Intuniv™ QL Kapvay™ QL

Drug Class	The following products will remain <i>preferred</i> products:	The following products will become <i>preferred</i> products:	The following products will become <i>non-preferred</i> products and require prior authorization (PA):	The following products will remain <i>non-preferred</i> products and require prior authorization (PA):
	mixed amphetamine salts IR ^{CC, QL} Quillivant™ XR ^{CC, QL} Vyvanse™ ^{CC, QL}			<i>methamphetamine</i> ^{QL} <i>Methylin</i> ® ^{QL} solution ^{QL} <i>methylphenidate (Generic for Metadate CD)</i> ^{QL} <i>methylphenidate chewable (Generic for Methylin</i> ® ^{QL} chewable tablets) ^{QL} <i>methylphenidate LA (Generic Ritalin LA</i> ® ^{QL}) ^{QL} <i>methylphenidate solution</i> ^{QL} <i>mixed amphetamine salts ER</i> ^{QL} <i>Procentra</i> ™ ^{QL} <i>QuilliChew ER</i> ™ ^{QL} <i>Ritalin</i> ® ^{QL} <i>Ritalin LA</i> ® ^{QL} <i>Zenzedi</i> ™ ^{QL}
Oral Anti-Arrhythmics	amiodarone 100, 200 mg disopyramide flecainide mexiletine procainamide propafenone quinidine gluconate ER quinidine sulfate quinidine sulfate ER Sorine® sotalol sotalol AF	dofetilide	<i>Tikosyn</i> ®	amiodarone 400 mg Betapace® Betapace® AF dofetilide Multaq® Norpace® Norpace® CR Pacerone® propafenone SR Rythmol® SR Sotylize®
Familial Hypercholesterolemia Agents Lipotropics: Bile Acid Sequestrants Lipotropics: Cholesterol Absorption Inhibitors Lipotropics: Fibric Acid Derivatives	Kynamro™ ^{CC} cholestyramine cholestyramine light colestipol tablets Prevalite® gemfibrozil	ezetimibe fenofibrate nanocrystallized (generic Tricor®) fenofibric acid (generic Trilipix™)	Zetia® TriCor® Trilipix™	Juxtapid™ Colestid® colestipol granules/packets Questran® Questran Light® WelChol® Antara™ Fenoglide™ fenofibrate (generic Antara™, Lipofen™, Lofibra®) fenofibric acid (generic Fibracor™)

Drug Class	The following products will remain <i>preferred</i> products:	The following products will become <i>preferred</i> products:	The following products will become <i>non-preferred</i> products and require prior authorization (PA):	The following products will remain <i>non-preferred</i> products and require prior authorization (PA):
				Fibricor™ Lipofen™ Lopid® Triglide™
Lipotropics: Omega-3 Fatty Acids Lipotropics: Niacin Derivatives Lipotropics: PCSK9 Inhibitors	Lovaza® ST Niaspan®			<i>omega-3 acid ethyl esters</i> Vascepa® Niacor® niacin niacin ER Praluent® ^{CC} Repatha™ ^{CC}

New Sedative Hypnotic Maximum Duration Edit

Requests for long-term (more than 60 days per year) use of sedative hypnotics will be approved for 6-month periods when the following conditions are met:

- Patient has been evaluated for signs and symptoms of abuse, dependency, misuse or overuse of controlled substances including KASPER monitoring; AND
- Patient has had a trial (at least 3 weeks) of non-pharmacological therapies (e.g., stimulus control, sleep restriction, sleep hygiene measures, and relaxation therapy); AND
- Patient has a diagnosis of severe or refractory insomnia; AND/OR
- Patient has a comorbid condition (e.g., psychiatric disorder, chronic pain) which causes and/or exacerbates insomnia; AND/OR
- Patient requires use of a sedative hypnotic medication to maintain compliance with nighttime breathing apparatus (e.g., CPAP); OR
- A Clinical Pharmacist may approve the request if there is another valid medical reason why the recipient requires long-term use of the requested medication.
- Approval of requests beyond 60 days should be limited to non-benzodiazepine agents (e.g., eszopiclone, suvorexant, zaleplon, zolpidem) wherever possible due to the higher potential for abuse, dependency, and withdrawal associated with benzodiazepines. Benzodiazepine sedative hypnotics (e.g., estazolam, flurazepam, temazepam, triazolam) should only be approved for long-term use when:
 - Patient has tried and failed a non-benzodiazepine sedative hypnotic (e.g., eszopiclone, suvorexant, zaleplon, zolpidem) or is unable to use these agents due to allergy or contraindication which does not apply to benzodiazepine sedative hypnotics; AND
 - Patient meets all other above criteria for exceeding the duration limit.

Note: Each member will be allowed 60 days of sedative hypnotic use from the date the edit takes effect.

Consent Agenda

The therapeutic classes in the table below were reviewed; no changes were made to the currently posted status for agents in these classes.

- Antianginal & Anti-Ischemic
- Antibiotics, Topical
- Anticoagulants
- Bronchodilators, Beta-Agonists
- Calcium Channel Blockers
- Laxatives & Cathartics
- Oncology Oral - Other
- Ophthalmics, Allergic Conjunctivitis
- Ophthalmics, Anti-inflammatories
- Ophthalmics, Antibiotic-Steroid Combinations Ophthalmics, Antibiotics
- Ophthalmics, Antivirals
- Ophthalmics, Glaucoma
- Ophthalmics, Mydriatics
- Platelet Aggregation Inhibitors
- Proton Pump Inhibitors
- Thrombopoiesis Stimulating Proteins

New Products to Market

Drugs Requiring PA	Criteria
<p>Nerlynx™</p>	<p><i>Non-prefer in the PDL class: Oral Oncology Agents, Breast Cancer</i></p> <p>Length of Authorization: 1 year</p> <ul style="list-style-type: none"> Nerlynx™ (neratinib) is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage human epidermal growth factor receptor 2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. <p>Criteria for Approval:</p> <ul style="list-style-type: none"> Diagnosis of early stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer; AND Previous treatment with Herceptin® (trastuzumab) within the past 2 years. <p>Age Limit: ≥ 18 years</p> <p>Quantity Limit: 6 tablets per day</p>
<p>Syndros™</p>	<p><i>Non-prefer in the PDL class: Oral Anti-Emetics: Δ-9-THC Derivatives</i></p> <p>Length of Authorization: 6 months</p> <ul style="list-style-type: none"> Syndros™ (dronabinol) oral solution is a cannabinoid indicated in adults for the treatment of anorexia associated with weight loss in patients with AIDS as well as nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. It is available as a 5 mg/mL oral solution in 30 mL bottles. NOTE: The DEA has classified Syndros™ as C- II, indicating that this liquid formulation may have a higher potential for addiction, abuse and/or misuse than dronabinol capsules, which are C-III. <p>Criteria for Approval:</p> <ul style="list-style-type: none"> Clinically valid reason (e.g., feeding tube, swallow study) that dronabinol capsules cannot be used; AND No history of hypersensitivity to, or abuse of, alcohol; AND Diagnosis of nausea and vomiting associated with cancer chemotherapy; AND Have failed to respond adequately to at least 1 other anti-emetic therapy; OR Diagnosis of anorexia associated with weight loss in a patient with AIDS. <p>Age Limit: ≥ 18 years</p> <p>Quantity Limits:</p> <p><i>AIDS Anorexia:</i> 3 mL per day</p> <p><i>Chemotherapy Nausea and Vomiting:</i> 8 mL per day</p>

Drugs Requiring PA	Criteria
Tremfya™	<p>Non-prefer in the PDL class: <i>Immunomodulators</i></p> <p>Length of Authorization: 1 year</p> <ul style="list-style-type: none"> • Tremfya™ (guselkumab) is a monoclonal antibody that functions as an interleukin-23 (IL-23) antagonist; it is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is available as a 100 mg/mL pre-filled syringe for subcutaneous injection. <p>Criteria for Approval:</p> <ul style="list-style-type: none"> • Diagnosis of moderate to severe plaque psoriasis; AND • Symptoms persistent for ≥ 6 months with at least 1 of the following: <ul style="list-style-type: none"> ○ Involvement of at least 10% of body surface area (BSA); OR ○ Psoriasis Area and Severity Index (PASI) score of 12 or greater; OR ○ Incapacitation due to plaque location (i.e., head and neck, palms, soles or genitalia); AND • Negative tuberculosis (TB) screening prior to initiating treatment; AND • Trial and failure of two of the following therapies: <ul style="list-style-type: none"> ○ Methotrexate ○ Cyclosporine ○ Oral retinoid (e.g., Soriatane®, acitretin) ○ Topical corticosteroids ○ Phototherapy/UV light ○ Coal tar preparations; AND • Trial and failure of, or contraindication to, a preferred immunomodulator (i.e., Enbrel® or Humira®). <p>Renewal Criteria:</p> <ul style="list-style-type: none"> • Patient continues to meet criteria identified above; AND • Ongoing monitoring for TB; AND • Disease response as indicated by improvement in signs and symptoms compared to baseline, such as redness, thickness, scaliness, and/or the amount of surface area involvement. <p>Age Limit: ≥18 years</p> <p>Quantity Limit:</p> <p><i>Loading Dose:</i> 2 syringes per 56 days</p> <p><i>Maintenance Dose:</i> 1 syringe per 56 days</p>

Drugs Requiring PA	Criteria
Mavyret™	<p>Prefer with Clinical Criteria in the PDL class: <i>Hepatitis C: Direct-Acting Antiviral Agents</i></p> <p>Length of Authorization: Duration of treatment course (8, 12, or 16 weeks)</p> <ul style="list-style-type: none"> Mavyret™ (glecaprevir/pibrentasvir) is a fixed-dose combination product containing glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor (PI), and pibrentasvir, an HCV NS5A inhibitor. It is indicated for the treatment of HCV genotypes 1 to 6 in adult patients without cirrhosis or with compensated cirrhosis (Child-Pugh A). It is also indicated to treat HCV in patients who have genotype 1 and have been treated previously with regimens containing either an HCV NS5A inhibitor or an HCV NS3/4A PI, but not both. Mavyret™ is available as tablets for oral administration containing 100 mg glecaprevir and 40 mg pibrentasvir; the recommended dosing is 3 tablets once daily. <p>Criteria for Approval:</p> <ul style="list-style-type: none"> Diagnosis of chronic hepatitis C virus (HCV) infection; AND Patient does not have a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy; AND Patient is NOT pregnant; AND Must be prescribed by, or in consultation with, a gastroenterologist, hepatologist, or infectious disease provider; AND Must be evaluated for liver disease severity and have no cirrhosis or compensated cirrhosis (Child-Pugh A); AND Must be screened for Hepatitis B Virus (HBV) infection prior to treatment; AND Must be prescribed for an FDA-labeled and/or AASLD-recommended treatment course regarding cirrhosis status, genotype, and prior treatment experience. Requests for repeat treatment are subject to additional criteria. <p>Age Limit: ≥ 18 years</p> <p>Quantity Limit: 3 tablets per day</p>

Drugs Requiring PA	Criteria
Vosevi™	<p>Prefer with Clinical Criteria in the PDL class: <i>Hepatitis C: Direct-Acting Antiviral Agents</i></p> <p>Length of Authorization: 12 weeks</p> <ul style="list-style-type: none"> Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir), a fixed-dose combination product containing sofosbuvir, a hepatitis C virus (HCV) NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, is indicated for the treatment of chronic HCV infection in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have genotypes 1-6 infection and previously received treatment with an NS5A inhibitor, or who have genotype 1a or 3 HCV infection and have been treated previously with sofosbuvir without an NS5A inhibitor. Vosevi™ is available as a fixed-dose combination tablet containing 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir; the recommended dosing is 1 tablet daily. <p>Criteria for Approval:</p> <ul style="list-style-type: none"> Diagnosis of chronic hepatitis C virus (HCV) infection; AND Patient does not have a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy; AND Patient is NOT pregnant; AND Must be prescribed by, or in consultation with, a gastroenterologist, hepatologist, or infectious disease provider; AND Must be evaluated for liver disease severity and have no cirrhosis or compensated cirrhosis (Child-Pugh A); AND Must be screened for Hepatitis B Virus (HBV) infection prior to treatment; AND Patient must be evaluated for alcohol and substance abuse using a validated screening tool with appropriate follow up to address addiction as part of HCV treatment; AND Abstinence from alcohol and illicit substances confirmed by laboratory testing; AND Treatment-experienced with an NS5A inhibitor (e.g., daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir); OR Genotype 1a or 3 and treatment-experienced with sofosbuvir without an NS5A inhibitor (e.g., daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir). <p>Age Limit: ≥18 years</p> <p>Quantity Limit: 1 tablet per day</p>

Drugs Requiring PA	Criteria
Idhifa[®]	<p><i>Non-prefer in the PDL class: Oral Oncology Agents, Hematologic Cancer</i></p> <p>Length of Authorization: 1 year</p> <ul style="list-style-type: none"> • Idhifa[®] (enasidenib) is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test. It is available as 50 mg and 100 mg tablets for oral administration. <p>Criteria for Approval:</p> <ul style="list-style-type: none"> • Diagnosis of relapsed or refractory acute myeloid leukemia (AML); AND • Presence of an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test; AND • Not pregnant. <p>Renewal Criteria:</p> <ul style="list-style-type: none"> • Continue to meet above criteria; AND • Clinical response or lack of disease progression. <p>Age Limit: ≥18 years</p> <p>Quantity Limit: 1 tablet per day</p>



To review the complete summary of the final PDL selections and new products to market updates and changes, please refer to the “Commissioner’s Final Decisions from March 16, 2017” posted on the provider web portal at: <https://kyportal.magellanhealth.com> (by clicking the Resources/Documents/Committees/P&T tabs).

Thank you for helping Kentucky Medicaid members maintain access to prescription coverage by selecting drugs on the preferred drug list whenever possible. Please contact Magellan Medicaid Administration at kyproviders@magellanhealth.com for any additional information or questions you may have.

Sincerely,

Jade Range, CPhT

Jade Range, CPhT
Contracts Manager

kyproviders@magellanhealth.com

Kentucky Medicaid Fee-for-Service Pharmacy Program’s Contact Information		
Clinical Support Center	1-800-477-3071 Sunday – Saturday 24 hours a day	Please contact the Clinical Support Center to request a prior authorization (PA) or to check the status of a request. NOTE: The only drugs that are now required to be submitted via fax are Brand Medically Necessary, Buprenorphine products, Synagis®, and Zyvox®.
Pharmacy Support Center	1-800-432-7005 Sunday – Saturday 24 hours a day	Please contact the Pharmacy Support Center when claims assistance is required. Timely filing, lock-in, and early refill (ER) overrides can be obtained through this Call Center.
Provider Services	1-877-838-5085 Monday – Friday 8:00 a.m. – 4:30 p.m.	Please contact Provider Services if you have questions about enrollment or when updating your license or bank information.
Member Services	1-800-635-2570 Monday – Friday 8:00 a.m. – 5:00 p.m.	Please contact Member Services if you are a member or if you as the provider have questions regarding the member’s benefits or eligibility coverage dates.